Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Czechia

Marie Skłodowska-Curie Action · Running

FANTOM Future of ALCL: Novel Therapies, Origins, Bio-Markers and Mechanism of resistance

Coordinator
Masarykova univerzita, Czechia
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€2.6m
Total cost
—
Partners
22 organisations in 6 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072735

What the project is doing

In the project's own words, from its summary on CORDIS.

The FANTOM Doctoral Network (DN) composed of 7 beneficiaries and 12 associated partners in 5 EU countries, recruiting 10 researchers and will be embedded into an established international research programme: The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (ERIA) as well as a clinical network: The European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL). FANTOM will cosset and nurture the recruited researchers to become confident, competent, independent and well-connected European scientists with excellent career perspectives welcomed into these established networks.

This will be achieved through a training programme conducted through research and complemented by a balanced programme of transferable skills designed with key input from both academic and industrial collaborators. The training of each fellow will be guided by an individual career development plan and supervised by a PhD committee with clearly allocated academic and industrial supervisors. The primary goal of the network is to train the recruited fellows by participation in an internationally competitive research programme and integrating them into the aforementioned networks.

The research programme will address the clinical problems posed by Anaplastic Large Cell Lymphoma (ALCL) typified by aberrant ALK expression. Applying innovative model systems and multi-omics technologies, some performed to a single cell level, the biology of ALCL including the roles of the immune system and tumour stroma will be uncovered. These data will be applied to the development of (non-invasive) biomarkers and novel therapeutic approaches that will culminate in the design of clinical trials to address the issues of chemotherapy toxicity, over-treatment and drug resistance.

The research and training activities will incorporate not only academic labs but also key research institutes, biotechnology companies, clinical trial bodies and Pharma to realise our research goals.

Topics

Who is involved

OrganisationCityCountryRole
Masarykova univerzitaBrnoCzechiaCoordinator
Biolution GmbHWienAustriaAssociatedpartner
Cbmed GmbHGrazAustriaAssociatedpartner
Medizinische Universitaet WienWienAustriaParticipant
Open Science - Lebenswissenschaften Im DialogWienAustriaAssociatedpartner
THT Biomaterials GmbHWienAustriaAssociatedpartner
Albert-Ludwigs-Universitaet FreiburgFreiburgGermanyAssociatedpartner
Gpoh Gemeinnutzige GmbHBerlinGermanyAssociatedpartner
Gpoh Zdm GgmbhHannoverGermanyAssociatedpartner
Klinikum Der Technischen Universität München (tum Klinikum)MuenchenGermanyParticipant
Miltenyi Biotec BV & Co KgBergisch GladbachGermanyAssociatedpartner
Mll Munchner Leukamielabor GmbHMunchenGermanyAssociatedpartner
Universitaetsklinikum FreiburgFreiburgGermanyParticipant
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyParticipant
Galseq srlBressoItalyAssociatedpartner
Universita Degli Studi Di PadovaPadovaItalyParticipant
Universita Degli Studi Di TorinoTorinoItalyParticipant
Universita' Degli Studi Di Milano-BicoccaMilanoItalyParticipant
European Hematology AssociationDen HaagNetherlandsAssociatedpartner
Naked Science LtdCambridgeUnited KingdomAssociatedpartner
Pangaea DataLondonUnited KingdomAssociatedpartner
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI